iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors Pharmaceutical Investing
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Pharmaceutical Investing
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023 Pharmaceutical Investing
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook Pharmaceutical Investing
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility Pharmaceutical Investing
Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial Pharmaceutical Investing
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office Pharmaceutical Investing
